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Aims/hypothesis: The adipose tissue-derived hormone leptin plays an important role in the maintenance of body weight and glucose ho-
meostasis. Leptin mediates its effects by interaction with leptin receptors (LepRb), which are highly expressed in the hypothalamus and other
brain centres, and at lower levels in the periphery. Previous studies have used relatively promiscuous or inefﬁcient Cre deleter strains,
respectively, to explore the roles of LepR in pancreatic b and a cells. Here, we use two newly-developed Cre lines to explore the role of leptin
signalling in insulin and proglucagon-expressing cells.
Methods: Leptin receptor expression was measured in isolated mouse islets and highly-puriﬁed islet cells by RNASeq and quantitative RT-PCR.
Mice lacking leptin signalling in pancreatic b, or in a and other proglucagon-expressing cells, were generated using Ins1Cre- or iGluCre-mediated
recombination respectively of ﬂox’d leptin receptor alleles. In vivo glucose homeostasis, changes in body weight, pancreatic histology and
hormone secretion from isolated islets were assessed using standard techniques.
Results: Leptin receptor mRNA levels were at or below the level of detection in wild-type adult mouse isolated islets and puriﬁed cells, and leptin
signalling to Stat3 phosphorylation was undetectable. Whereas male mice further deleted for leptin receptors in b cells exhibited no abnormalities
in glucose tolerance up to 16 weeks of age, females transiently displayed improved glucose tolerance at 8 weeks (11.2  3.2% decrease in area
under curve; p < 0.05), and improved (39.0  13.0%, P < 0.05) glucose-stimulated insulin secretion in vitro. No differences were seen
between genotypes in body weight, fasting glucose or b/a cell ratio. Deletion of LepR from a-cells, a minority of b cells, and a subset of
proglucagon-expressing cells in the brain, exerted no effects on body weight, glucose or insulin tolerance, nor on pancreatic hormone secretion
assessed in vivo and in vitro.
Conclusions/interpretation: The use here of a highly selective Cre recombinase indicates that leptin signalling plays a relatively minor, age-
and sex-dependent role in the control of b cell function in the mouse. No in vivo role for leptin receptors on a cells, nor in other proglucagon-
expressing cells, was detected in this study.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Type 2 Diabetes mellitus (T2D) currently affects approximately 380
million individuals worldwide [1] and is characterized by elevated blood
glucose levels. The treatment of T2D complications, which include
cardiovascular disease, retinopathy and peripheral nerve damage,
typically consumes 10e20% of the health care budgets of westernized
societies [2]. Whilst insulin, secreted from pancreatic islet b cells, acts
to lower blood glucose levels, glucagon, secreted by pancreatic a cells,
increases glycaemia. Defects in the release or actions of either hor-
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catalogue/PUB10364), is an important risk factor for T2D and pro-
motes both insulin resistance and b cell failure [4]. The adipose tissue-
derived hormone leptin is an important satiety factor which acts on the
feeding centres in the brain to suppress appetite [5]. Human mutations
in either the leptin (obese, or ob) [6,7] or the leptin receptor (LepR) [8]
gene lead to severe obesity from an early age. Demonstrating a
conserved role for the hormone across mammalian species, mice
carrying mutations in the homologous genes (ob/ob [9] or db/db) [10]
display severe hyperphagia, obesity and disturbed glucose
homeostasis.and Metabolism, Department of Medicine, Imperial College London, du Cane Road,
bridge, UK 3Centre for Cardiovascular and Metabolic Neuroscience, Department of
ion; KATP, ATP-sensitive K
þ channel; GTT, ITT, glucose and insulin tolerance test,
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Table 1 e Primer sequences.
Target Forward primer sequence 50-30 Reverse primer sequence 50-30
Tissue
control
FER2-Q2: accttcagaccttggcgttggagg FER2-R2: cctgaggttcctgttgctgtgactcc
Ins1Cre Cre jva rv 2:
gccagattacgtatatcctggcag
Cre jva fw 2: ttcactggttatgcggcgg
LepRF 103: tgagttccctcatgattctgg See below
LepRF 104: cagccgaccaatgcttatt 105: acaggcttgagaacatgaacac
iCre Cre002: gacaggcaggccttctctgaa Cre003: cttctccacaccagctgtgga
b-catenin RM41: aaggtagagtgatgaaagttgtt RM42: caccatgtcctctgtctattc
tdRFP Anti: ctacaggaacaggtggtgg Sense: ctgttcctggggcatggc
Original articleIn addition to the central actions of leptin, roles for the hormone have
also been suggested in the periphery. Thus, LepR expression has been
described in the endocrine pancreas [11,12], and several studies [12e
18] have reported an action of leptin to inhibit insulin secretion.
Furthermore, over-expression of insulin receptors in the islets of LepR-
deﬁcient Zucker diabetic fatty (ZDF) rats restores glucose-stimulated
insulin secretion (GSIS) [19]. Whether physiological concentrations of
leptin (1 nM) also inhibit secretion, however, has been contested [20].
Recent work [21] suggests that the actions of leptin on insulin release
involve the stimulation of AMPK-activation protein kinase (AMPK) and
trafﬁcking of ATP-sensitive Kþ (KATP) channels to the plasma mem-
brane. These changes are thus expected to impede the glucose-
dependent closure of KATP channels, voltage-gated Ca
2þ channel
opening and Ca2þ inﬂux that trigger insulin secretion in response to
glucose [22].
Using a Cre deleter strain driven by the rat insulin 2 promoter (RIP2)
Covey et al. [23] deleted critical ﬂox’d exons in the gene encoding the
active, long form of the leptin receptor (LepRb) in vivo in murine
pancreatic b cells and in a speciﬁc population of neurons in the hy-
pothalamus (RIP2Cre neurons). These animals developed obesity,
fasting hyperinsulinaemia, impaired glucose-stimulated insulin release
and glucose intolerance. On the other hand, Morioka et al. [24] dis-
rupted the leptin receptor in all pancreatic cells using a Pdx1 promoter-
driven Cre and these mice, in contrast, exhibited normal body weight,
improved glucose tolerance and elevated plasma insulin. However,
when challenged with high fat diet, Pdx1Cre:LepRF/F mice became
glucose intolerant.
The difference between these studies is thus likely to be the result of
using different Cre lines and hence deletion in partially overlapping, but
different, cell types: crucially, in neither case was the leptin receptor
deleted exclusively in pancreatic b cells. Thus, the RIP2Cre promoter
used by Covey et al. is active in b cells and also in several areas of the
brain, particularly in the hypothalamus [25]. By contrast, the Pdx1Cre
used by Morioka et al. is expressed in adult b-cells and also deletes in
glucagon-secreting pancreatic a cells as well intestinal glucagon-like
peptide 1- (GLP-1) secreting L-cells and several other cell types with
roles in glucose homeostasis [26]. The Pdx1Cre line also deletes in
neuronal populations responsive to leptin [25].
Our ﬁrst aim here, therefore, was to examine the effects of deleting the
long form of the leptin receptor (LepRb) highly selectively in pancreatic b
cells using the novel Ins1Cre deleter strain [27,28]. Selectivity with this
strain is achieved ﬁrstly by the use of the Insulin I promoter, whose
expression is essentially conﬁned to pancreatic b cells [29]. By contrast,
the Insulin II gene, which drives RIP2Cre promoter expression, is
expressed in multiple brain regions [25,30]. Secondly, precise devel-
opmental and spatial control of Cre expression by Ins1Cre is enhanced by
its targeted insertion (knock-in) at the Ins1 locus. Finally, this line also
avoids risks associated with the use of other insulin promoter-driven
Cres [31] of Cre-independent actions due to co-expression of growth
hormone. The present strategy is expected, therefore, to distinguish
between the actions of leptin on glucose homeostasis via the pancreatic
b cell and those acting via the brain and elsewhere.
The possibility has also recently been explored that leptin receptors
play a role in pancreatic a cells to control glucagon secretion [32].
However, whilst the latter studies failed to identify any defects in
glucose homeostasis after LepR deletion using a Cre expressed under
the control of a short fragment of the glucagon promoter [33],
recombination was only achieved in w43% of a cells. Correspond-
ingly, we [34] and others [35,36] have similarly found that the latter
Cre deletes in only a minority (13e45%) of a cells. This leaves open
the possibility that the effects of deletion described by Tuduri et al. [32]620 MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsemight be masked by changes in the remaining, non-recombined a cell
population. To test this hypothesis, our second aim here was to use an
alternative glucagon promoter-driven Cre, iGluCre [37], based on a
much longer (w100 kB) region upstream of the proglucagon gene,
which drives recombination in the vast majority of a cells. However,
Cre is also expressed with this line at other sites of proglucagon
expression including the nucleus tractus solitarius (NTS) of the hind-
brain [38], and in intestinal L-cells, both of which express leptin re-
ceptors [37,39]. Both of these cell types secrete the incretin glucagon-
like peptide-1 (GLP-1) and thus impaired leptin receptor signalling,
particularly in the neuronal population [40], might affect body weight,
glucose homeostasis, or both.
2. MATERIALS AND METHODS
2.1. Generation of mice
Mice bearing LepRF alleles on an FVB background were kindly provided
by Dr Streamson Chua (Columbia University) and, after backcrossing
twice to C57BL/6 mice, bred to Ins1Cre [28] or iGluCre [37] mice
(C57BL6 background) as indicated. Further crosses to Rosa26tdRFP
were performed with iGluCreLepRF/F mice to allow labelling of
recombined cells. Animals (2e5) were maintained in separately
ventilated cages in a speciﬁc pathogen-free environment. All pro-
cedures were approved by the U.K. Home Ofﬁce and were compliant
with the Animals (Scientiﬁc Procedures) Act 1986 of the United
Kingdom (PPL 70/7349). Genotyping was performed as described ([41]
and see Results). Primer sequences are given in Table 1.
2.2. Studies of glucose homeostasis and hormone release in vivo
Intraperitoneal glucose (1 g/kg) or insulin (0.75 U/mL) tolerance tests
were performed on mice fasted for 16 h or 5 h, respectively, as
described [42], using an automated glucometer (Accucheck, Roche,
Burgess Hill, U.K.). Plasma insulin and glucagon levels were measured
with ELISA kits from Cis Bio (Bagnols-sur-Cèze, France) and Mercodia
(Uppsala, Sweden), respectively.
2.3. Assay of insulin and glucagon secretion from isolated islets
Islet isolation by collagenase injection and pancreatic distension was
performed as described [43]. Islets were cultured for 24e36 h in RPMI
medium supplemented with 10% foetal calf serum, 100 U/mL peni-
cillin and 100 mg/mL streptomycin. Hormone release was measured
during 30 or 60 min (insulin or glucagon, respectively) static incubation
of batches of six (insulin) or 20 (glucagon) islets in 0.5 mL modiﬁed
Kreb’s Ringer medium comprising (mM): 120 NaCl, 4.8 KCl, 24
NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2 MgCl2 and 5 D-
glucose, pH 7.4, at 37 C. Secreted and total hormone levels were
measured by homogeneous time-resolved ﬂuorescence-based (HTRF)
assay (Cisbio).vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.4. Intracellular free Ca2þ imaging and connectivity analysis
Imaging was performed at 34e36 C essentially as described [44].
Brieﬂy, islets were loaded with Fluo2 (Teﬂab) and Ca2þ signals
captured with a Nipkow spinning disk coupled to a Zeiss Axiovert
M200 microscope ﬁtted with x10ex20/0.3e0.5 numerical aperture
(NA) objectives (EC Plan-Neoﬂuar, Zeiss). Cells were illuminated at
491 nm using a solid state laser (Cobalt) with emitted light detected
from 500 to 550 nm using a 16-bit back-illuminated EM-CCD
(Hamamatsu C9100-13). Connectivity analysis was performed as
described [44].
2.5. Immunocytochemical analysis
2.5.1. tdRFP and glucagon
Animals were anaesthetised with ketamine and transcardially
perfused-ﬁxed with 4% PFA before post-ﬁxation for 1 h and embed-
ding in parafﬁn and sectioning. Sections were labelled with anti-RFP
(Rockland, 600-401-379, 1:50 dilution, secondary-Alexa 568 1:250)
and anti-glucagon (1:500 dilution, secondary-Alexa 488 1:250) and
anti-glucagon (1:500 dilution, secondary-Alexa 488 1:250) antibodies
and sealed using Vectashield hardset mounting medium with DAPI
(Vector Laboratories).
2.5.2. Insulin and glucagon
Mouse pancreata were extracted and ﬁxed in 10% (v/v) neutral buff-
ered formalin at 4 C for 18 h before parafﬁn embedding and
sectioning. Sections were labelled with polyclonal anti-insulin (Dako
A4056, 1:200 dilution, Secondary-Alexa 488 1:1,000) or anti-glucagon
(Sigma, G2654 or Santa Cruz, sc-13091, 1:200 dilution, Secondary-
Alexa 568 1:500) antibodies and sealed using Vectashield hardset
mounting medium with DAPI (Vector Laboratories). Fluorophores were
excited using a Zeiss Observer Vivatome and a 20x/NA 0.8 x objective
and 365 nm, 470-nm and 540e580-nm LEDs. Emission was detected
using Semrock ﬁlters centred on 377/50 nm, 472/30 nm, and 534/
20 nm for DAPI, Alexa 488, and Alexa 568, respectively.
2.6. Islet isolation and FACS sorting
Transgenic mice (males and females, >16 weeks) expressing the
ﬂuorescent proteins Venus under the control of the proglucagon pro-
moter [45], or EYFP under the control of the prosomatostatin [46]
promoter (>8 week old mice) were euthanized by cervical disloca-
tion and the pancreas injected immediately with 5 ml of collagenase V
(0.5 mg/ml) in Ca2þ and Mg2þ-free HBSS. Pancreata were digested
and the islets hand-picked into HBSS containing 0.1% fatty acid-free
bovine serum albumin (BSA) and 11 mM glucose. Islets were dis-
rupted into single cells by trituration following incubation for 1 min in
Ca2þ-free HBSS containing 0.1x trypsin/EDTA and 0.1% BSA. Cells
were immediately sorted by ﬂow cytometry using a BD Inﬂux cell sorter
(BD Biosciences, San Jose, CA, USA) equipped with a 488 laser for
excitation of Venus or EYFP. To collect alpha and beta cells, Venus-
positive and negative cells were collected, with the latter further
subdivided into a population that was large (according to side and
forward scatter) and with high background autoﬂuorescence at 530
and 580 nm. To collect delta cells, only EYFP positive cells were
collected. Cells were collected into RLT lysis buffer (QIAGEN) and
frozen on dry ice.
2.7. Massive parallel sequencing (RNASeq)
Details of RNASeq for whole islets, and subsequent data analysis, are
provided in [27]. For studies on individual islet cell types, total RNA was
extracted using an RNeasy Micro Plus kit (Qiagen, Manchester, UK)MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsevier GmbH. This is an
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Ovation RNA-seq System V2 (PN 7102, NuGEN) whereby 2.5 ng of RNA
for each sample was used (3, 2, and 4 replicates were used each for a,
b, and d cells, respectively, totalling 9 samples). To prepare the RNA-
seq library, the ampliﬁed cDNA (3 mg per sample) was fragmented to
200 bp using the Bioruptor Sonicator (Diagenode) and barcode ligation
and end repair were achieved using the Ovation Rapid DR Library
System (PN 0319,0320, NuGEN). The barcoded libraries were com-
bined and sent for SE50 sequencing using an Illumina HiSeq 2500
system at the Genomics Core Facility, Cambridge Institute, CRUK.
2.8. Quantitative RT-PCR
Total RNA was extracted using an RNeasy Micro kit (QIAGEN, UK),
according to the manufacturer’s protocol. Superscript III (Life tech-
nologies) reverse transcriptase was used to synthesize cDNA.
Analysis was performed with a 7900 HT Fast Real-Time PCR system
(Applied Biosystems). The PCR reaction mix consisted of ﬁrst-strand
cDNA template, primer pairs for LepR, forward primer binding exon
junction 16e17 (GTTTCACCAAAGATGCTATCGAC) and reverse primer
binding exon 17 (GAGCAGTAGGACACAAGAGG), and PCR Master mix
(Applied Biosystems). Expression of selected targets was compared
with that of Cyclophilin measured on the same sample in parallel on
the same plate.
2.9. Immunocytochemical analysis of Stat3 phosphorylation
Islets were incubated for 30 min in Kreb’s Ringer bicarbonate buffer
followed by incubation with either leptin (10 nM), IL1-b (50 ng/mL) and
TNF-a (1000 pg/mL) or control conditions at 37 C. Islets were ﬁxed in
4% PFA for 1 h at 4 C.
Antigen retrieval steps were performed by incubating islets in 0.01 M
Tris-HCl for 5 min at 90 C, before cooling to room temperature and
incubation in 100% methanol at 20 C for 10 min. Free-ﬂoating
islets were stained immunohistochemically with anti-pSTAT3 (pTyr-
705; NEB, 4113S, 1:100 dilution, secondary-Alexa 488 1:500) and
anti-insulin (1:200 dilution, secondary-Alexa 488 1:500) antibodies,
and mounted onto glass slides, as above. Images were obtained by
using a Zeiss LSM-780 microscope and a 60x/NA 0.8 x objective.
2.10. Statistical analysis
Statistical signiﬁcance was assessed using Student’s t-test with
Bonferroni correction, or two-way ANOVA, as indicated, using Graph-
Pad Prism 6.0. P-values < 0.05 were considered signiﬁcant. Values
are presented as means  S.E.M.
3. RESULTS
3.1. LepR mRNA levels are low in isolated mouse islets and in
puriﬁed islet cells
We ﬁrst assessed expression of leptin receptors in isolated islets and
highly puriﬁed preparations of islet cells from wild-type mice (Materials
and Methods) using RNASeq and quantitative RT-PCR. LepR mRNA
was detected at 0.2 RPKM in whole islets [27], at the lower 39th centile
of all messages, and 0.23, 0.036 and 0 RPKM in puriﬁed b, d and a
and cells, respectively (n ¼ 3, 2 and 4 separate preparations,
respectively). Correspondingly, whereas qRT-PCR ampliﬁed LepR
mRNA from whole islets (not shown), this approach failed to amplify a
product from any of the three isolated cell preparations (Figure 1AeC).
By contrast, the primers used efﬁciently ampliﬁed LepR mRNA from
hypothalamus-derived polyAþ mRNA (Figure 1D). Consistent with low
levels of LepR protein in islets, staining of islets with ﬂuorescently-
labelled Cy3-leptin [12] failed to reveal consistent signals aboveopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 621
Figure 1: Low levels of LepR mRNA and receptor signalling in puriﬁed islet cells and whole islets, respectively. Ampliﬁcation plot of LepR (red) or Ppia (cyclophilin, green)
using mRNA puriﬁed from mouse islet (A) b (B) a or (C) d cells or (D) hypothalamus. (E) Immunoﬂuorescence staining of pStat3 in whole islets after treatment with either leptin
(10 nM), TNF-a and IL1-b, or control non-treated islets. Data are representative of two further experiments. Scale bar 52.5 mm. See the Materials and Methods section for further
details.
Original articlebackground (results not shown). To further test the hypothesis that
LepR signalling is low or undetectable in pancreatic islet cells, we
exposed isolated islets from wild type C57BL6 mice to either leptin, or
to a cytokine mixture (IL1-b and TNF-a) as a positive control, and
monitored Stat3 phosphorylation on Tyr 705 using immunocyto-
chemistry and laser-scanning confocal imaging. Whereas the cytokine
mixture caused a robust increase in Stat3 phosphorylation as antici-
pated, no effects were observed upon addition of leptin, even at the
highest dose (10 nM) tested (Figure 1E).
The above ﬁndings suggest that leptin receptor levels are vanishingly
low (b, d) or zero (a) in key islet cell types and limit the actions of the
hormone on this tissue.
3.2. Gender and age-dependent effects of LepR deletion from
pancreatic b cells
To ablate residual LepRb function selectively from pancreatic b cells,
animals bearing alleles in which LoxP sites ﬂank exon 17 of the leptin
receptor gene [41] were crossed with animals harbouring the Ins1Cre
transgene. Exon 17 includes the BOX1 domain required for leptin-
induced JAK-STAT signalling [41]. Based on the use of reporter622 MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsestrains [27], this approach is expected to lead to recombination in the
majority (>94%) of b cells, with <2% recombination in other islet cell
types [27], in the resulting Ins1CreLepRKO mice. To conﬁrm Cre-
mediated excision of exon 17 (LepRbD17), genomic DNA was isolated
from several tissues and PCR performed with two sets of primers as
indicated in Figure 2A [41]. PCR ampliﬁcation of DNA from islets derived
from LepRbF/F or Ins1CreLepRKO animals generated a product of 339 bp
and a band of 208 bp where Cre-mediated excision of exon 17 had
occurred (Figure 2B). Whilst attempts were made to conﬁrm deletion by
measuring full-length and truncated LepRb mRNA, levels these were
below the level of reliable quantitation both in LepRbF/F and Ins1Cre-
LepRKO mice, as discussed above, and in line with the absence of a
functional effect of leptin on islet pStat3 phosphorylation (Figure 1E).
Consistent with the absence of recombination and deletion of LepRb in
satiety centres in the hypothalamus, loss of LepRb mediated by
Ins1Cre in the b cell exerted no effect on body mass in Ins1CreLepRKO
mice (Figure 2C). Neither fasting glucose (Figure 2D,E) nor plasma
insulin (Figure 2F,G) was different between wild-type and null mice.
Since both the previously-described leptin receptor-deﬁcient mice
generated by recombination with RIP2Cre [23] or Pdx1Cre [24] animalsvier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Ins1Cre expression results in excision of the ﬂox’d region of LepRb alleles selectively in islets. Genomic DNA was harvested from Ins1CreLepRKO and control
LepRF/F animals and used as a template for PCR with the primers indicated (A). Predicted product sizes are 339 bp for the ﬂox’d allele (primers b,c) and 207 bp for the excised
allele (primers a,c) (B). Ins1CreLepRKO animals displayed a normal progression in bodyweight. Ins1CreLepRKO males (green line) and LepRF/F (black line) and below Ins1CreLepRKO
females (red line) and LepRF/F (black line). (C). Blood glucose concentration after overnight fast in males (D) (Ins1CreLepRKO, n ¼ 8, LepRF/F, n ¼ 7) and females at 8 weeks (E)
(Ins1CreLepRKO, n ¼ 13, LepRF/F, n ¼ 9). Plasma insulin levels in male mice (F) Ins1CreLepRKO, n ¼ 10, LepRF/F n ¼ 7, and in females (G) Ins1CreLepRKO, n ¼ 9, LepRF/F, n ¼ 7.
b to a cell ratio in Ins1CreLepRKO and wild-type mice (H).display an abnormal b cell area, b to a cell ratio was examined in
Ins1CreLepRKO animals. No changes in this parameter were apparent
(Figure 2H).
To examine in more detail whether disruption of leptin signalling in b
cells affected glucose metabolism, animals aged 8, 12 and 16 weeks
were subjected to intraperitoneal glucose tolerance tests (IPGTT). At 8
weeks, female Ins1CreLepRKO null mice showed transiently improved
glucose tolerance, which reversed by 16 weeks (Figure 3A,B). No
glycaemic phenotype was identiﬁed in male Ins1CreLepRKO at any of
the ages examined (Figure 3C,D). Ins1CreLepRKO mice also displayed
normal insulin sensitivity (Figure 4A).
3.3. Impact of LepRb deletion on b cell glucose signalling and
insulin secretion
Given the reported role of leptin to inhibit insulin secretion [23,24], we
measured insulin secretion in Ins1CreLepRKO mice in vivo and in vitro.
No differences in the excursions in plasma insulin concentration were
observed during intraperitoneal glucose tolerance tests between
Ins1CreLepRKO mice and littermate controls (Figure 4B). Glucose- (16.7
vs 3 mM) stimulated insulin secretion was signiﬁcantly potentiated
in vitro in LepRb-deleted islets from 30 week old female, but not male
Ins1CreLepRKO mice (Figure 4C). These changes, which may reﬂect
the lower variability of measurements performed in isolated islets, are
consistent with the observed small improvements in glucose tolerance
(Figure 3A).MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsevier GmbH. This is an
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impair glucose-dependent Ca2þ signals [47]. However, this observation
was ascribed partly to the effects of the RIP2Cre transgene itself [31], as
well as to the loss of LepRb. Contrary to the latter ﬁndings, deletion of
LepRb with Pdx1.Cre potentiated glucose-induced Ca2þ oscillations. To
examine the effect of LepRb deletion more selectively in the b cell we
therefore monitored changes in intracellular free Ca2þ ([Ca2þ]i) in
response to high glucose, or depolarisation with KCl, in islets from 8
weeks old female Ins1CreLepRKO or control mouse islets. Islets lacking
LepRb in b cells displayed a tendency towards lower [Ca2þ]i increases in
response to high glucose (Figure 5A), though this difference was not
signiﬁcant when hundreds of single cells were individually assessed
within each micro-organ to exclude outliers which confound signal
analysis (i.e. glucose non-responsive cells, and those cells displaying
large and sustained increases indicative of apoptosis). Likewise, no
changes in response to stimulationwith KCl (not shown), or inb cell-b cell
connectivity (Figure 5B,C), [44], were observed in Ins1CreLepRKO mice
versus control littermates suggesting that b cell population responses to
glucose remain coordinated even in the absence of LepRb signalling.
3.4. Role of leptin receptors in pancreatic a- and other
proglucagon-expressing cells
Leptin has been reported to exert a direct inhibitory effect on glucagon
secretion from isolated mouse and human islets [48]. To generate
animals deleted for the LepRb in pancreatic a cells and otheropen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 623
Figure 3: Ins1CreLepRKO females display improved glucose tolerance at the age of 8 weeks. (A) Blood glucose concentration following IPGTT in Ins1CreLepRKO (square
symbol) and LepRF/F littermate controls (triangles) in 8-week old females: Ins1CreLepRKO, n ¼ 13, LepRF/F, n ¼ 9, (B) 16-week old females: Ins1CreLepRKO, n ¼ 15, LepRF/F,
n ¼ 17, (C) 8-weeks old males: Ins1CreLepRKO, n ¼ 8, LepRF/F, n ¼ 7, (D) 16-week old males: Ins1CreLepRKO, n ¼ 13, LepRF/F, n ¼ 10. For all panels, the corresponding body
weight and area under curve (AUC) are inset. Data are expressed as the average  SEM. Statistical analysis was performed using two-way ANOVA *P < 0.05.
Original articleproglucagon-expressing cells (including GLP-1-expressing intestinal L-
cells and GLP-1-positive neurons in the brain), LepRb ﬂox’d animals
[41] were crossed with animals harbouring the iCre recombinase
transgene under the control ofw100 kB region immediately upstream
of the proglucagon gene [37]. The resulting iGluCreLepRKO mice were
further crossed to Rosa26.tdRFP reporter mice [49].624 MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by ElseIn order to conﬁrm ﬁrstly the deletion of LepRb in target cells, genomic
DNA was harvested from several different tissues and brain areas and
PCR was performed using primers ﬂanking the LoxP sites (Methods;
Figure 6A). The presence of the recombined allele was clearly detected
in islets, and to a lesser extent in the olfactory bulb, the nucleus tractus
solitarius (NTS) and intestine. Correspondingly, in mice carrying thevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 4: Enhanced glucose-stimulated insulin secretion in Ins1CreLepRKO females. (A) Blood glucose after IP injection of insulin in Ins1CreLepRKO (square symbol) and
LepRF/F littermate controls (triangles) in males and females (n ¼ 9e10 mice per genotype). (B) Plasma insulin levels after IP injection of glucose in males and females:
Ins1CreLepRKO, n ¼ 10, LepRF/F, n ¼ 6. (C) Insulin secretion as assessed from isolated islet in response to glucose (LG ¼ 3 mM, HG ¼ 17 mM) and KCl (30 mM) in 30-week old
female and male mice. n ¼ 3 separate experiments involving 2e3 mice per genotype/experiment. Statistical analysis was performed using two-way ANOVA *P < 0.05.Rosa26.tdRFP reporter, red ﬂuorescence was clearly apparent in the
majority of glucagon-positive a cells (Figure 6B), but not in
Rosa26.tdRFP mice lacking iGluCre (Figure 6C). In the presence of the
Cre transgene, recombination occurred in the vast majority (w80%) of
glucagon-positive islet cells, but also in a minority (w20%) of insulin-
positive b cells (Figure 6B,D).
No differences in growth curves were apparent between iGluCre-
LepRbKO and LepRbF/F mice (Figure 7A), nor were differences in fasting
blood glucose detected (Figure 7B). Intraperitoneal glucose
(Figure 7C,D) and insulin (Figure 7E,F) tolerance were also identical
between genotypes. Likewise, there were no apparent differences in
glucagon release in response to hypoglycaemia in vivo (Figure 7G), nor
in vitro in response to low or high glucose (Figure 7H). A tendency for
leptin (10 nM) to impair glucagon release at low glucose was apparent
in wild-type, but not iGluCreLepRbKO mice (Figure 7H).
4. DISCUSSION
4.1. Leptin receptor signalling in b cells
The studies described herein present the ﬁrst examination to our
knowledge of the impact of highly selective abrogation of leptin
receptor function in pancreatic b cells using Ins1Cre-mediated
deletion. We show ﬁrstly that levels of leptin receptor mRNA and ofMOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comleptin signalling are vanishingly low in highly puriﬁed mouse islet
cells and whole islets, respectively (Figure 1). These results
corroborate work from Fujikawa, Coppari and colleagues [50] who
showed, through the use of a leptin receptor promoter Cre crossed
to Rosa26RFP reporter mice, that RFP expression (reﬂecting the
activity of the LepR promoter) is essentially undetectable in the
endocrine pancreas, both during development and in adult mice. In
contrast, recombination was detected in a more poorly-deﬁned cell
population outside of the islet, possibly corresponding to duct cells
or ductal precursors. Importantly, the latter cells are likely to
contaminate islets after isolation, and, as such, may reﬂect the
major pool of LepRb-expressing cells in these ex vivo preparations.
Consequently, the use of Cre deleter strains active throughout the
pancreas, notably Pdx1Cre, is expected to cause recombination and
loss of LepRb from these contaminating (non-islet) cells. The loss of
LepRb mRNA apparent in islets from the above mice in a previous
report [24], therefore, seems likely to reﬂect deletion from the above
population other than from b-cells per se. We note that the report by
Covey et al. [23] using the Rip2Cre deleter strain, and therefore
expected in the pancreas to delete only in b cells, does not include
any data on LepRb mRNA levels in wild type versus null mouse
islets. Only measures of DNA recombination, as performed in our
own study, were provided.open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 625
Figure 5: Ins1CreLepRKO islets display impaired Ca2D responses to high glucose. Ca2þ recordings from control LepRF/F islets (black line) and Ins1CreLepRKO islets (red line)
in response to either 11 mM glucose (A). Inset are area under the curve (AUC) and amplitudes (DF (Fmax-Fmin)) of the Ca
2þ rises. Data are from 14 to 16 islets (3e4 mice) per
genotype. (B,C) Connectivity analysis [44] showing the proportion (%) of signiﬁcantly correlated cell pairs during a step change from 3 to 11 mM glucose (i.e. the activity onsets), or
at steady state in the continued presence of 11 mM glucose. Pseudocolor plots in (C) show the strength of connections, determined using by Pearson Correlation (Pearson R). Data
are expressed as mean  SEM. Statistical analysis was performed using two-way ANOVA and Student’s t-test. *P < 0.05.
Original articleNevertheless, and consistent with earlier ﬁndings using more pro-
miscuous Cres [23,24], we show that the levels of leptin receptors on
b cells may be sufﬁcient to restrict b cell function in vivo under some
circumstances. Thus, we report mild glycaemic effects of LepRb
deletion which appeared transiently in female mice (Figure 3A,B).
Although challenged by the ﬁndings of Coppari and colleagues [50]
(above) one possibility, not explored here, is that this might reﬂect a
transiently higher level of expression of leptin receptors on b cells at
this developmental stage in females. However, the alternative possi-
bility that a very low level of LepR expression, perhaps on a minority of
well-connected (“pacemaker” or “hub”) b cells [51], is sufﬁcient to
exert islet-wide consequences on insulin secretion in juvenile females,
cannot be discounted.
We note that, whilst in one previous report [23] the effects of b cell-
targeted LepRb deletion were examined using oral glucose tolerance
tests (OGTTs), in a second paper [24], equally dramatic effects of
deleting these receptors throughout the pancreas were observed using
IPGTTs, where peak blood glucose was reduced from w22 to 16
(27%) and from >16 to w9.5 mM (40%) in 6 month old males and
females, respectively. Our own experiments, using the more selective
Ins1Cre driver line to delete LepRb, revealed a much more modest
reduction in peak glucose during IPGTT, fromw12 to 10 mM (16%) in
8 week old females, whereas no differences were observed between
control and knockout male mice of the same age, or between 4 month
old mice of either sex (Figure 3). The measurements in the present626 MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsestudy are thus best compared to the latter report [24], using IPGTTs,
and support our contention of a limited role for LepR in b cells beyond
juvenile stages. The more marked effects of LepRb deletion described
in earlier studies [23,24] would seem to be attributable, at least in
large part, to the loss of leptin receptors at other sites, notably the
brain, with consequent effects on food intake (and hence insulin
sensitivity) [23] or potentially in other non-endocrine pancreatic cells
[24]. Interestingly, Morioka et al. [24] did not observe changes in body
weight after Pdx1Cre-mediated deletion, whilst markedly elevated
insulin secretion and b cell mass were reported.
A potential concern with the present studies is that deletion may not
have occurred throughout the b cell complement, as we have assumed
[27]. Whilst LepRb mRNA levels were too low to quantitate accurately
either in wild type or Ins1CreLepRKO islets (Figure 1AeC), we believe
this possibility to be unlikely. Firstly, we observed clear recombination
at the genomic level in isolated islets (Figure 2B). Secondly, Ins1Cre
leads to highly efﬁcient recombination at LoxP sites in other targets
including in LKB1/STK11, AMPKa1 and a2 alleles [27], at the Rosa26-
eYFP locus [28], and in mice carrying a single halorhodopsin allele
downstream of a LoxP-STOP-LoxP cassette (D.J.H. and G.A.R. results
not shown). In the two latter models, recombination is observed in
97.8% and 94.7% of b cells, respectively.
Further supporting a limited role of LepRb on b cells are studies by
Chua and colleagues [52] demonstrating an absence of metabolic
phenotype in mice deleted selectively for LepR in the periphery. In lightvier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: iGluCre expression results in recombination of LepRb ﬂox’d alleles in the olfactory bulb, nucleus tractus solitarius, intestine and pancreatic islets. Genomic
DNA was harvested from the tissues indicated and used as a template for PCR with primer pair a and c (as indicated in Figure 1A). Predicted product sizes are 625 bp for the ﬂox’d
allele and 207 bp for the excised allele. (A) PCR transcript of the excised alleles in iGluCreLepRKO and LepRF/F controls. Immunohistochemical analysis of pancreas from iGlu-
Cre:tdRFPStopFlox mice, bearing wild type LepR alleles (B) stained for RFP (red), glucagon (green) and DAPI (blue), and in control animals without Cre (tdRFPStopFlox) (C). Quan-
tiﬁcation of the percentage of RFP expressing a and b cells (D). n ¼ 39 islets from three animals. Data are expressed as mean  SEM.of the above observations, our own data in Ins1CreLepRKO animals
reporting only a weak metabolic phenotype are not entirely
unexpected.
Interestingly, the inhibitory actions of leptin observed in the present
study appear to be independent of glucose-induced increases in
intracellular Ca2þ, since the latter showed only a non-signiﬁcant
tendency to be impaired in Ins1CreLepRKO mice (Figure 5).
4.2. Leptin receptor signalling in a cells
Using the less efﬁcient PPG.Cre [33], earlier studies [32] have reported
that elimination of LepRb from a subset of a cells exerted no effect on
glucose tolerance. However, and consistent with ﬁndings from Tuduri
et al. [48], we observed a tendency for leptin to inhibit glucagon
secretion in vitro (Figure 7G), an effect which was abolished in iGlu-
CreLepRbKO mouse islets. Similarly, a tendency was observed towards
a more rapid recovery towards normal glycaemia after insulin injection
in female KO mice (Figure 7F). Thus, at least under the conditions
examined here, leptin receptor signalling in a cells has no more than aMOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.commarginal role at most in the control of glucagon secretion during
hypoglycaemia.
4.3. Leptin receptors in GLP-1 neurons
In the present study, we failed to observe differences in weight gain
between wild-type and iGluCreLepRbKO mice. Whilst the simplest
interpretation of these data would be that GLP-1-expressing neurones
in the NTS are not involved in the control of food intake, we note that
Scott and colleagues [53] recently observed that disruption of LepRb
signalling in this brain region using a less selective Phox2B deleter
strain led to hyperphagia but not weight gain. This was attributed to an
increase in energy expenditure in null mice. Whether deletion of LepRb
using the iGluCre transgene similarly affected food intake is a possibility
which will require testing in individually-housed mice in the future.
4.4. Leptin receptors in other proglucagon-expressing cells
Intestinal L-cells, which synthesise and secrete GLP-1, are also an
important site of proglucagon expression, and consequentlyopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 627
Figure 7: iGluCreLepRKO mice display normal glucose tolerance and fasting blood glucose levels. (A) Body weight followed for 30 weeks in male (green) and female (red)
iGluCreLepRKO and LepRF/F mice (n ¼ 12e19 mice per genotype). (B) Fasting blood glucose levels in 8 week old males and females (n ¼ 6e11 mice per genotype). (C,D) Blood
glucose concentration after IPGTT in male and female iGluCreLepRKO (square symbol) and LepRF/F (green triangle) mice. Blood glucose concentration after ITT in males: (E)
iGluCreLepRKO, n ¼ 8, LepRF/F, n ¼ 7; and females: (F) iGluCreLepRKO, n ¼ 8, LepRF/F, n ¼ 10. Plasma glucagon levels during ITT, iGluCreLepRKO, n ¼ 6, LepRF/F, n ¼ 4, (G), and
glucagon release from isolated islets in the presence of the indicated glucose concentrations: LG ¼ 0.5 mM, HG ¼ 10 mM glucose; n ¼ 6 animals per genotype (H). When present,
leptin was added to 10 nM. Data are expressed as the mean  SEM and statistical comparison was through two-way ANOVA, *p < 0.05. Other details are provided in the Materials
and Methods section.
Original articlerecombination in iGluCre mice [37,38]. Although not measured directly
in the present studies, changes in GLP-1 output from these cells would
seem to be unlikely in iGluCreLepRKO mice given their unaltered body
weight gain (Figure 7A) and glucose tolerance (Figure 7C,D), as well as
the low expression of leptin receptor mRNA in FACS-puriﬁed mouse L-
cells (FR and FMG, data not shown).628 MOLECULAR METABOLISM 4 (2015) 619e630  2015 The Authors. Published by Else5. CONCLUSIONS
Using a well-deﬁned and efﬁcient Cre deleter strain we demonstrate
that leptin signalling in b cells plays a physiologically relevant, albeit
very limited role, to control insulin secretion in vivo. Similarly, leptin
has a relatively minor, if any, role in the control of glucagon secretionvier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
from pancreatic a cells. No direct evidence was obtained in the present
study for a role for leptin receptors in GLP-1-expressing cells in the gut
or brain.
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